Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 4/20 | 0.32 |
| ▸ | CCND1 | P24385 | 4/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.32 |
| ▸ | PRKACA | P17612 | 2/20 | 0.31 |
| ▸ | PRKACG | P22612 | 2/20 | 0.31 |
| ▸ | PRKACB | P22694 | 2/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846120 | 0.73 | ESR1 (0.31) | CCR8KMT2A | |
| SCHEMBL12846128 | 0.72 | CHEK1 (0.42) | CHEK1CDK4CCND1 | |
| SCHEMBL12845915 | 0.71 | CDK4 (0.64) | PARP1CHEK1CDK2CDK4CCND1 | |
| SCHEMBL11517007 | 0.66 | GSK3B (0.35) | CHEK1WEE1CDK2CDK4CCND1 | |
| SCHEMBL2086780 | 0.64 | PARP1 (1.00) | PARP1 | |
| SCHEMBL14495382 | 0.63 | CFB (0.37) | CCR8KMT2A | |
| SCHEMBL10262821 | 0.61 | P2RX7 (0.41) | PARP1KMT2A | |
| SCHEMBL13991817 | 0.60 | CCR8 (0.36) | PARP1CCR8KMT2A | |
| SCHEMBL820394 | 0.60 | CCR8 (0.37) | CCR8KMT2A | |
| SCHEMBL2542070 | 0.60 | TNF (0.45) | PARP1PRKACACCR8KMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066324-B1 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | MLKL, PARP3, PARP1 | PARP1 3/4885CHEK1 193/4885WEE1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.